Ianalumab’s Success in Phase III Trials Marks a Turning Point in Sjögren’s Disease

By News Health
52 minutes Ago

(MedPage Today) — In the recently reported NEPTUNUS-1 and -2 trials, presented at this year’s American College of Rheumatology (ACR) annual meeting, investigators found that the anti-B-cell activating factor receptor (BAFF-R) antibody ianalumab…

Source link : https://www.medpagetoday.com/meetingcoverage/acrexpertroundtable/118909

Author :

Publish date : 2025-12-09 16:45:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

PA- and Physician-Led Heart Transplant Recovery Comparable

Novel Orexin Drug Improves Cognitive Symptoms of Narcolepsy Type 1

New BTK Inhibitor Makes Case for Earlier Use in CLL

Novel ITP Drug Helps Patients Ditch Daily Meds

FDA Probes RSV Drug Safety; Why Some Cancers Shouldn't Be Treated; New Mpox Strain

GLP-1s and Cancer: Meta-analysis Shows Little or No Link